Indication
HGBL
1 clinical trial
2 products
Clinical trial
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2025-01-01
Product
131-I ApamistamabProduct
CAR T-cell